Harnessing chicken antibodies to overcome challenges of anti-GPCR antibody generation and providing new antibody candidates for difficult druggable targets.
Focus: Therapeutics Commencement date: June 1, 2016 Location:JLABS @ Toronto
There are about 400 druggable genes historically known to be intractable, but with a huge validated therapeutic potential, such as the G protein-coupled receptors (GPCRs), ion channels and integrins. These membrane proteins are notoriously difficult targets for antibody generation because they occur in low density on the cell surface and, once purified from the membrane, they are very unstable, thus presenting a challenge in obtaining sufficient amounts of immunogen in which native epitopes are maintained for antibody recognition. The result: only a handful of antibodies are currently tested in clinical trials. This is a major opportunity since antibodies currently represent the fastest growing class of drugs and membrane proteins represent an underexploited group of validated targets.
To capture the full potential of chicken antibodies, we have designed a multidisciplinary approach that combines bioinformatics, chemistry, physics, as well as biology, to create the best therapeutic entities.To circumvent these historical bottlenecks, we have designed 4 families of technologies to discover and engineer antibodies against these high potential targets:
Smart antigens, such as rationally designed Spatial Peptides that replicate the native 3D structure of targets,
Chicken antibodies as a novel source of therapeutics,
Phage display technologies to select the best antibodies, and
Humanization technologies to engineer the perfect immunotherapy agents
We have a very ambitious goal at Immune Biosolutions: save 1 million lives by 2025. For us, using science to solve major health issues of the developed world, as well as of emerging countries, by combining different scientific expertises to create the next-generation immunotherapies is very motivating. Science + Creativity = Innovation —> Impact on patients
Meet the Team:
Jean-François Larrivée, Ph.D. (c) Immunology Vice-President and COO
Simon Gaudreau, Ph.D. Immunology Vice-President and Chief Scientist
Frédéric Leduc, Ph.D. Biochemistry CEO
Yolaine Robitaille, M.Sc., MBA Business Development Director